Scott: I bet you have never heard of Nutraceutix<g>
It is an OTC.BB domestic company, which has been having somewhat interesting news in the past 3 months.
The price has been creeping up slowly since it reported better earnings back on November 15 and the following day they reported a deal with Temple University School of Pharmacy for development of controlled delivery of oral dosage forms of pharmaceuticals.
This week they had some news on agreements for development of controlled delivery of a pain medication (Tramadol)and today for the controlled delivery of Ma Huang.
Today it closed at $0.57 up 14% on volume of 62,700 <g>
Here is a copy of the aforementioned news:
REDREDMOND, Wash.--(BW HealthWire)--Nov. 15, 2000--Nutraceutix Inc. (OTC BB: NUTX - news) reports third quarter net revenues of $2,229,065 with net earnings of $442,035.
This compares to revenues of $3,460,522 with a profit of $244,900 for the three months ending Sept. 30, 1999.
For the nine months ended Sept. 30, 2000, net revenues totaled $6,232,536 with a profit of $98,894 compared to the net loss of $33,591 on total revenues of $7,782,963 for the corresponding period in 1999.
The decreased revenues during the third quarter of 2000 reflect the loss of the CDT(TM)/MDT(TM) androstiene business of MET-Rx USA / Rexall Sundown as a result of their cancellation of all in-house orders for products containing androstiene in response to the Food and Drug Administration review of the regulations surrounding the sale of androstiene products
MOND, Wash.--(BW HealthWire)--Nov. 16, 2000--Nutraceutix Inc. (OTC BB: NUTX - news), has recently acquired the exclusive, worldwide rights to a newly issued patent (U.S. Patent No. 6,090,411) from Temple University School of Pharmacy, Philadelphia, for the development of controlled delivery, oral dosage forms of pharmaceuticals, Over-the-Counter (OTC) products, and dietary/health supplements (nutraceuticals).
This is the second drug delivery patent developed in the laboratory of Dr. Reza Fassihi, Ph.D., that has been licensed to Nutraceutix Inc., a leading provider of new technologies to the pharmaceutical, OTC, and nutraceutical industries.
This technology may be a milestone in delivery technology since it addresses many of the challenges common to delivery systems that are currently available.
The new technology has been experimentally implemented into a range of established pharmaceuticals, such as nifedipine, theophylline, propanolol, diltiazem, and verapamil.
According to David T. Howard, president & chief executive officer of Nutraceutix Inc., ``This new patent provides Nutraceutix with a clear technological advantage over first generation, controlled delivery systems. We will seek to partner with major pharmaceutical, OTC, and nutritional companies to co-develop products incorporating Nutraceutix' technology platforms.''
Management anticipates that it will be late in the year 2001 before any revenues may be realized from this new acquisition.
Nutraceutix Inc. possesses proven technologies and products for the nutraceutical industry. In addition to patented ingredients like Calcium D-Glucarate, Nutraceutix provides patented and proprietary technologies like CDT(TM) Controlled Delivery Technology, MDT(TM) Molecular Dispersion Technology, S.E.T(TM) Self Emulsifying Technology and LiveBac® Probiotics.
Nutraceutix technologies provide distinctive supplements with tangible benefits for the consumer and competitive commercial advantages. For more information on Nutraceutix, please call 800/548-3222, or visit www.nutraceutix.com.
REDMOND, Wash.--(BW HealthWire)--Jan. 24, 2001--Nutraceutix Inc. (OTCBB: NUTX - news), a leading provider of proven technologies and products for the nutraceutical and pharmaceutical industries, has entered into an agreement with Lehigh Valley Technologies, Allentown, Pa., to co-develop Tramadol, a prescription pain medication, utilizing patented controlled delivery technology (CDT(TM)).
Last year, Nutraceutix Inc. acquired exclusive worldwide rights on CDT(TM), U.S. Patent 6,090,411, from Temple University School of Pharmacy, Philadelphia, for the over-the-counter (OTC) and prescription drug markets, as well as the dietary supplement and nutraceutical markets.
The companies will develop controlled delivery formulations of Tramadol to provide predictable, long-lasting pain relief. CDT(TM) technology will ensure a steady, programmed release of the active ingredient over time for optimum absorption.
Tramadol, a widely prescribed, synthetic analgesic, is not a non-steroidal anti-inflammatory drug (NSAID), and does not counteract the effects of certain anti-hypertensive substances, such as diurectics, beta blockers and ACE-inhibitors.
A common problem in pain management with the widespread use of NSAIDs is people not receiving optimal pain relief and also the lack of compliance associated with patients having to take multiple doses daily in order to help control pain.
Tramadol is currently marketed in the United States by Johnson & Johnson and is only available in an immediate-release, three to four doses per day format. Sales for the existing immediate-release version of Tramadol for the year ending July 2000 were in excess of $475 million.
David T. Howard, president and chief executive officer of Nutraceutix, stated, ``We are pleased to be working with Lehigh Valley Technologies once again. Our first license of CDT(TM) technology in the OTC store brand market with Lehigh Valley Technologies involved decongestants.
``With these two new novel CDT(TM) prescription analgesics, we address pain relief, one of the most prevalent and debilitating health concerns. The co-development of CDT(TM) Tramadol is an important step in the growth of Nutraceutix's prescription drug franchise, and we anticipate realizing revenues from this partnership after 2005.''
Nutraceutix Inc. possesses proven technologies and products for the nutraceutical industry. In addition to patented ingredients like Calcium D-Glucarate, Nutraceutix provides patented and proprietary technologies like CDT(TM) Controlled Delivery Technology, MDT(TM) Molecular Dispersion Technology, SET(TM) Self Emulsifying Technology and LiveBac® Probiotics.
Nutraceutix technologies provide distinctive supplements with tangible benefits for the consumer and competitive commercial advantages. For more information on Nutraceutix, please call 800/548-3222, or visit www.nutraceutix.com.
REDMOND, Wash.--(BW HealthWire)--Jan. 30, 2001--Nutraceutix Inc. (OTCBB:NUTX - news) has recently made available to the nutritional supplement industry Controlled Delivery Technology (CDT(TM)) Ma Huang.
This patented CDT direct compression pre-blend of Ma Huang, one of the most popular and widely used herbal ingredients in the health food and sports nutrition markets, is now available in six- and 12-hour release profiles.
CDT(TM) Ma Huang represents a major innovation for the already strong sports nutrition market, which sources estimate experienced a 12 percent growth in sales from 1998 to 1999 to amass $4.7 billion, with no signs of stagnating (Nutrition Business Journal, December 2000).
Following protein powders, sales of thermogenic products, including Ma Huang, reached an impressive $300 million in sales.
Patented CDT(TM) Ma Huang is formulated to eliminate the negative side effects commonly associated with conventionally dosed and released Ma Huang-containing supplements, such as a spike of the ingredient and the sudden tapering of its effects.
CDT(TM) ensures a precise delivery of Ma Huang continually over time to help regulate the herb's desirable benefits, such as enhanced metabolism, energy and alertness.
For dietary supplement manufacturers, the new DC pre-blend offers improved flow characteristics for high throughput tabletting and encapsulation. The result is enhanced product differentiation and performance.
Nutraceutix Inc. makes available either pre-blended ingredient for manufacturing, or contract tabletting and encapsulation at Nutraceutix' Colorado facility. For the highest quality Ma Huang with the added advantage of CDT(TM)'s superior delivery technology, contact Nutraceutix Inc.
Nutraceutix Inc. possesses proven technologies and products for the nutraceutical industry. In addition to patented ingredients like Calcium D-Glucarate, Nutraceutix provides patented and proprietary technologies like CDT(TM) Controlled Delivery Technology, MDT(TM) Molecular Dispersion Technology, SET(TM) Self Emulsifying Technology and LiveBac® Probiotics. |
